Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a biotechnology company incorporated in Canada, has successfully completed an exempt offering of securities, raising $2.4 million USD as per a new notice filed with the U.S. Securities and Exchange Commission (SEC) on January 11, 2024. The offering, which did not last more than a year, included equity, options, warrants, and other rights to acquire securities. The company, led by CEO Dr. Adi Zuloff-Shani, has indicated that none of the proceeds will be used for payments to its executive officers, directors, or promoters. Aegis Capital Corp. was involved in the transaction, receiving sales commissions estimated at $192,000 USD. The offering was made under Rule 506(b) of Regulation D, which allows for the sale of securities without SEC registration, provided certain conditions are met. Clearmind Medicine has confirmed that all securities have been sold, with a total of 12 investors participating in the offering.
Clearmind Medicine Inc., a biotechnology company incorporated in Canada, has successfully completed an exempt offering of securities, raising $2.4 million USD as per a new notice filed with the U.S. Securities and Exchange Commission (SEC) on January 11, 2024. The offering, which did not last more than a year, included equity, options, warrants, and other rights to acquire securities. The company, led by CEO Dr. Adi Zuloff-Shani, has indicated that none of the proceeds will be used for payments to its executive officers, directors, or promoters. Aegis Capital Corp. was involved in the transaction, receiving sales commissions estimated at $192,000 USD. The offering was made under Rule 506(b) of Regulation D, which allows for the sale of securities without SEC registration, provided certain conditions are met. Clearmind Medicine has confirmed that all securities have been sold, with a total of 12 investors participating in the offering.
根据2024年1月11日向美国证券交易委员会（SEC）提交的新通知，在加拿大注册的生物技术公司Clearmind Medicine Inc. 已成功完成证券的豁免发行，筹集了240万美元。此次发行持续不超过一年，包括股票、期权、认股权证和其他收购证券的权利。该公司由首席执行官阿迪·祖洛夫-沙尼博士领导，表示所得款项均不会用于向其执行官、董事或发起人付款。Aegis Capital Corp. 参与了这笔交易，获得的销售佣金估计为19.2万美元。此次发行是根据D条例第506（b）条进行的，该条允许在满足某些条件的情况下在没有美国证券交易委员会注册的情况下出售证券。Clearmind Medicine证实，所有证券均已出售，共有12名投资者参与了此次发行。
根据2024年1月11日向美国证券交易委员会（SEC）提交的新通知，在加拿大注册的生物技术公司Clearmind Medicine Inc. 已成功完成证券的豁免发行，筹集了240万美元。此次发行持续不超过一年，包括股票、期权、认股权证和其他收购证券的权利。该公司由首席执行官阿迪·祖洛夫-沙尼博士领导，表示所得款项均不会用于向其执行官、董事或发起人付款。Aegis Capital Corp. 参与了这笔交易，获得的销售佣金估计为19.2万美元。此次发行是根据D条例第506（b）条进行的，该条允许在满足某些条件的情况下在没有美国证券交易委员会注册的情况下出售证券。Clearmind Medicine证实，所有证券均已出售，共有12名投资者参与了此次发行。
有用
没用